Exhibit 99.3
August 28, 2023
Subject: Exciting New Chapter for Thorne
Today marks the beginning of an exciting new chapter for Thorne.
We’ve announced that we entered into a definitive agreement to be acquired by L Catterton, a market-leading consumer-focused investment firm. Once the transaction is complete, we will continue to operate as Thorne HealthTech, but as a privately-held company. You can read the press release here.
We have worked tirelessly to deliver on our mission to bring science-based solutions to the prevention space and empower consumers to live healthier lives longer. L Catterton brings an impressive track record of fostering the growth and success of leading global consumer brands. Together with their deep expertise in the health & wellness industry, global reach and extensive operational capabilities, I am confident L Catterton is the right partner to fuel Thorne’s long-term growth.
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. At that point, we will continue to operate as Thorne HealthTech, with business continuing as usual. We will continue to offer the highest quality, pure products you have come to trust.
We look forward to working closely with L Catterton to expand our offering and better serve you, our valued customers.
Thank you for your continued patronage and support.
| | |
Paul Jacobson | | Tom McKenna |
Chief Executive Officer | | Chief Operating Officer |
Additional Information and Where to Find It
In connection with the proposed acquisition of Thorne HealthTech, Inc. (“Thorne”), Healthspan Merger Sub, Inc. (“Purchaser”) will commence a tender offer for all of the outstanding shares of Thorne. The tender offer has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities of Thorne. It is also not a substitute for the tender offer materials that Purchaser will file with the Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. The solicitation and offer to buy the outstanding shares of Thorne will only be made pursuant to an offer to purchase and related tender offer materials. At the time of the commencement of the tender offer, Purchaser will file tender offer materials on Schedule TO with the SEC, and Thorne will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
1